Welcome to our dedicated page for ExcelFin Acquisition news (Ticker: XFIN), a resource for investors and traders seeking the latest updates and insights on ExcelFin Acquisition stock.
ExcelFin Acquisition Corp (XFIN) provides investors with comprehensive coverage of this SPAC's strategic initiatives and regulatory milestones. This centralized resource aggregates official press releases, merger disclosures, and sector-specific developments across healthcare, fintech, and technology markets.
Key updates include business combination announcements, SEC filings, leadership changes, and partnership disclosures. Investors gain timely access to materials critical for evaluating this blank check company's progress in identifying acquisition targets.
All content undergoes verification against primary sources including EDGAR filings and corporate communications. The archive enables historical performance analysis while maintaining strict neutrality regarding investment decisions.
Bookmark this page for structured access to ExcelFin's evolving transaction pipeline and regulatory updates. Cross-reference materials with market data using Stock Titan's financial tools for complete due diligence.
Baird Medical, a leading microwave ablation (MWA) medical device developer in China with recent expansion into the U.S. market, and ExcelFin Acquisition Corp (NASDAQ: XFIN) have completed their business combination. The resulting company, Baird Medical Investment Holdings (PubCo), will begin trading on Nasdaq under the symbols 'BDMD' and 'BDMDW' on October 2, 2024.
At ExcelFin's special meeting, 99.9% of votes cast approved the business combination. Upon completion, founders of Baird Medical and Grand Fortune Capital, subscribed to a $4,900,000 Convertible Preferred investment in the Company. The transaction involved various advisors, including Dechert LLP, Allen Overy Shearman Sterling US LLP, and Cohen & Company Capital Markets, among others.
Baird Medical, a leading microwave ablation (MWA) medical device developer in China, and ExcelFin Acquisition Corp (NASDAQ: XFIN) have announced the effectiveness of Baird Medical Investment Holdings 's registration statement on Form F-4. This marks a important step towards Baird Medical becoming a publicly-traded company on Nasdaq through their proposed business combination.
ExcelFin has scheduled a Special Meeting of Stockholders for September 26, 2024, to approve the business combination. The transaction is expected to close shortly after stockholder approval and satisfaction of other customary closing conditions. Stockholders are urged to review the proxy statement/prospectus and other relevant documents filed with the SEC for important information about the proposed transaction.
ExcelFin Acquisition Corp. (Nasdaq: XFIN) announced that as of December 13, 2021, holders of its initial public offering units can separately trade Class A common stock and warrants. The Class A common stock will trade under the ticker XFIN, while the warrants will trade under XFINW. Each unit consists of one share of Class A common stock and one-half of a redeemable warrant, with whole warrants exercisable at $11.50 per share. Units not separated will continue trading as XFINU.
ExcelFin Acquisition Corp. (NASDAQ: XFIN) has priced its initial public offering (IPO) at
FAQ
What is the current stock price of ExcelFin Acquisition (XFIN)?
What is the market cap of ExcelFin Acquisition (XFIN)?
